In acute chest syndrome in sickle cell disease, which antibiotic coverage is recommended?

In acute chest syndrome in sickle cell disease, which antibiotic coverage is recommended?

• A. Third-generation cephalosporin with azithromycin
• B. Narrow-spectrum penicillin only
• C. Vancomycin alone
• D. Amoxicillin

Answer: (A)

Acute chest syndrome in sickle cell disease is treated empirically as a pneumonia-like illness, so the antibiotic plan must cover both typical respiratory pathogens and atypical bacteria that aren’t killed by beta-lactams alone. A third-generation cephalosporin provides strong IV coverage against common typical pathogens such as Streptococcus pneumoniae and Haemophilus influenzae. Adding a macrolide like azithromycin extends coverage to atypical organisms such as Mycoplasma and Chlamydophila, which are common in ACS presentations and would be missed by many beta-lactams alone. This combination therefore offers comprehensive initial coverage for hospitalized patients with ACS. Narrow-spectrum penicillin alone wouldn’t cover atypicals; vancomycin alone misses many Gram-negative and atypical pathogens; and amoxicillin lacks adequate coverage for Haemophilus influenzae and resistant pneumococci and is not appropriate as initial IV therapy for ACS.

Acute chest syndrome in sickle cell disease is treated empirically as a pneumonia-like illness, so the antibiotic plan must cover both typical respiratory pathogens and atypical bacteria that aren’t killed by beta-lactams alone. A third-generation cephalosporin provides strong IV coverage against common typical pathogens such as Streptococcus pneumoniae and Haemophilus influenzae. Adding a macrolide like azithromycin extends coverage to atypical organisms such as Mycoplasma and Chlamydophila, which are common in ACS presentations and would be missed by many beta-lactams alone. This combination therefore offers comprehensive initial coverage for hospitalized patients with ACS.

Narrow-spectrum penicillin alone wouldn’t cover atypicals; vancomycin alone misses many Gram-negative and atypical pathogens; and amoxicillin lacks adequate coverage for Haemophilus influenzae and resistant pneumococci and is not appropriate as initial IV therapy for ACS.